Selective Resistance to Parathyroid Hormone Caused by a Novel Uncoupling Mutation in the Carboxyl Terminus of Galpha s

A CAUSE OF PSEUDOHYPOPARATHYROIDISM TYPE Ib*

Wei-I. WuDagger , William F. SchwindingerDagger , Luis F. Aparicio§, and Michael A. LevineDagger

From the Dagger  Division of Pediatric Endocrinology and the Ilyssa Center for Molecular and Cellular Endocrinology, Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 and § Metabolic Disease Associates, Erie, Pennsylvania 16507

Received for publication, July 10, 2000, and in revised form, September 28, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Gs is a heterotrimeric (alpha , beta , and gamma  chains) G protein that couples heptahelical plasma membrane receptors to stimulation of adenylyl cyclase. Inactivation of one GNAS1 gene allele encoding the alpha  chain of Gs (Galpha s) causes pseudohypoparathyroidism type Ia. Affected subjects have resistance to parathyroid hormone (PTH) and other hormones that activate adenylyl cyclase plus somatic features termed Albright hereditary osteodystrophy. By contrast, subjects with pseudohypoparathyroidism type Ib have hormone resistance that is limited to PTH and lack Albright hereditary osteodystrophy. The molecular basis for pseudohypoparathyroidism type Ib is unknown. We analyzed the GNAS1 gene for mutations using polymerase chain reaction to amplify genomic DNA from three brothers with pseudohypoparathyroidism type Ib. We identified a novel heterozygous 3-base pair deletion causing loss of isoleucine 382 in the three affected boys and their clinically unaffected mother and maternal grandfather. This mutation was absent in other family members and 15 additional unrelated subjects with pseudohypoparathyroidism type Ib. To characterize the signaling properties of the mutant Galpha s, we used site-directed mutagenesis to introduce the isoleucine 382 deletion into a wild type Galpha s cDNA, transfected HEK293 cells with either wild type or mutant Galpha s cDNA, plus cDNAs encoding heptahelical receptors for PTH, thyrotropic hormone, or luteinizing hormone, and we measured cAMP production in response to hormone stimulation. The mutant Galpha s protein was unable to interact with the receptor for PTH but showed normal coupling to the other coexpressed heptahelical receptors. These results provide evidence of selective uncoupling of the mutant Galpha s from PTH receptors and explain PTH-specific hormone resistance in these three brothers with pseudohypoparathyroidism type Ib. The absence of PTH resistance in the mother and maternal grandfather who carry the same mutation is consistent with current models of paternal imprinting of the GNAS1 gene.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The term pseudohypoparathyroidism (PHP)1 (1) describes a group of disorders characterized by biochemical hypoparathyroidism (i.e. hypocalcemia and hyperphosphatemia), increased secretion of PTH, and target tissue unresponsiveness to the biological actions of PTH (1). Patients with PHP type I show neither a phosphaturic nor a nephrogenous cyclic AMP response to administration of exogenous PTH. These findings have implicated a defect in the PTH receptor-G-protein-adenylyl cyclase complex in cells of the proximal renal tubule as the basis for impaired PTH responsiveness. In one form of PHP, the type Ia variant (2), patients are resistant to PTH as well as multiple other hormones (3) that bind to receptors that are coupled by the stimulatory G protein (Gs) to activation of adenylyl cyclase. In addition to hormone resistance, patients with PHP type Ia also manifest a peculiar constellation of developmental and somatic defects, including short stature, round faces, brachydactyly, and subcutaneous ossifications, that are collectively termed Albright's hereditary osteodystrophy (AHO) (1). The diverse clinical manifestations of AHO have been attributed to heterozygous mutations in the GNAS1 gene that lead to widespread deficiency of the alpha  subunit of Gs (Galpha s) (4, 5). Although most subjects with GNAS1 mutations have hormone resistance, and thus PHP type 1a, in many families some members have AHO and normal hormone responsiveness, a condition termed pseudo-PHP (PPHP) (4-6). In a second form of PHP, termed type Ib, patients have normal Galpha s activity in accessible cells, lack features of AHO (7, 8), and have hormone resistance that is limited to PTH (3). Specific resistance of target tissues to PTH and normal Galpha s activity had implicated decreased expression or function of the classical or type 1 PTH receptor (PTHR1) that is expressed in bone and kidney as the cause for hormone resistance. However, molecular studies have failed to disclose mutations in the coding exons (9) and promoter regions (10) of the PTHR1 gene or its mRNA (11). Moreover, mice (12) and humans (13) in which one PTHR1 allele is inactivated do not manifest PTH resistance or hypocalcemia. Indeed, inheritance of two defective-type PTHR1 alleles results in Blomstrand chondrodysplasia, a lethal genetic disorder that is characterized by advanced endochondral bone maturation (13).

Most cases of PHP type Ib appear to be sporadic, but familial cases have been described in which transmission of the defect is most consistent with an autosomal dominant pattern (7, 14). Recent studies using linkage analysis have mapped the genetic locus for PHP type 1b to a small region of chromosome 20q13.3 near the GNAS1 gene, thus raising the possibility that some patients with PHP type Ib have inherited a GNAS1 mutation that leads to a selective defect in PTH-dependent signaling (15). In this report we describe a unique mutation in the GNAS1 gene that caused autosomal dominant PTH resistance in three brothers with PHP type Ib, but which was clinically silent in their mother and maternal grandfather. These findings confirm that discrete mutations in this G protein can produce a highly specific phenotype and provide additional evidence that imprinting of the GNAS1 gene may explain variable manifestations of the same mutation.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials

Bovine (Nle8,18,Tyr34)-PTH-(1-34)-amide peptide was purchased from Bachem (Torrence, CA). Human chorionic gonadotropin, bovine thyrotropic hormone (bTSH), and (-)-isoproterenol-(+)-bitartrate were purchased from Sigma. Plasmid containing the cDNA for the human TSH receptor was a generous gift of Dr. L. Kohn (National Institutes of Health), and plasmid containing the rat LH receptor was a generous gift of Dr. Deborah Segaloff (University of Iowa). The human kidney PTHR1 cDNA has been described previously (16). All receptor cDNAs were cloned into the expression vector pcDNAI/Amp (InVitrogen, Carlsbad, CA).

Methods

Analysis of Galpha s Protein-- Erythrocyte membranes were prepared by hypotonic lysis as described previously (17), and activity of detergent-solubilized Galpha s was determined by assessing reconstitution of hormone-sensitive adenylyl cyclase activity of S49 cyc membranes in the presence of 10 µM L-isoproterenol plus 0.1 mM GTPgamma S (18).

To prepare a particulate fraction (referred to as "membranes") from transfected HEK293 cells, cultured cells were incubated with a hypotonic lysis buffer (5 mM HEPES, pH 7.4, 0.5 mM EDTA) for 30 min at 37 °C and subsequently harvested by scraping with a Teflon policeman. Cells were disrupted by 20 strokes of a Dounce homogenizer (loose-fitting) on wet ice and then centrifuged at 480 × g for 10 min. The supernatant was collected and centrifuged at 27,000 × g for 30 min. Membranes were suspended in 25 mM HEPES and 1 mM dithiothreitol and stored at -70 °C until used.

Expression of Galpha s protein in erythrocyte and HEK293 membranes was determined by immunoblot analysis using 50-µg samples of membrane protein, as described previously (19), using a polyclonal antibody (RM/1) directed against a carboxyl terminus decapeptide of Galpha s (PerkinElmer Life Sciences). Levels of immunoreactive Galpha s protein were normalized to the level of Gbeta protein using a polyclonal antibody that reacts with the common forms of Gbeta . Protein was assayed with the BCA Protein Assay Reagent (Pierce) with BSA as a standard.

Identification of Mutation-- Exons 1-13 and the flanking intron sequences of the human GNAS1 gene were amplified by the polymerase chain reaction as described previously (20, 21) using genomic DNA from peripheral blood leukocytes. Amplified DNA fragments were analyzed first by polyacrylamide gel electrophoresis to assess the size of the fragments and then by DGGE to detect mutations (20). Amplified DNA fragments that migrated anomalously were precipitated with sodium acetate and ethanol and taken up in TE (10 mM Tris-HCl, 1 mM EDTA, pH 8) prior to ligation into the plasmid cloning vector pCRII (InVitrogen, Carlsbad, CA). DNA from individual clones was sequenced by dideoxynucleotide chain termination method (22) using Sequenase (U. S. Biochemical Corp.). Total cellular RNA was isolated from isolated mononuclear cells by the guanidinium isothiocyanate-cesium chloride technique (23), and RT-PCR was used to amplify a portion of Galpha s mRNA as described previously (24). One-fifth of the first strand cDNA served as a template in a 50-µl reaction with 50 pmol of sense primer 5' AM21 located in exon 8 and antisense primer 5' MAL21 located in exon 13 (20).

Construction of Expression Plasmids-- By using PCR, we introduced the Delta Ile382 mutation into a wild type human Galpha s cDNA (5) that contained a hemagglutinin epitope tag (codons 76-82, DVPDYAS) in exon 3 (25). Briefly, overlapping DNA fragments were amplified using the full-length human Galpha s cDNA as a template. The 5' fragment was amplified with upstream primer D1 (5'CAAGCAAGATCTGCTCGCTGAGA3') spanning the unique BglII restriction site and downstream primer D2 (5'TGCGCTGAATGTCACGGCAGTCGT3') spanning the 3-base pair deletion. The 3' fragment was amplified with upstream primer D3 (5'ACGACTGCCGTGACATTCAGCGCA3') spanning the 3-base pair deletion and downstream primer D4 (5'GTAGGCCGCCTTAAGCTTTCTAAAT3') spanning the unique HindIII restriction site. These PCR products were then mixed, denatured at 95 °C, and annealed together by cooling to 25 °C at 1 °C/s and then used as a template to amplify a BglII-HindIII cassette. The cassette was sequenced to confirm the introduction of the mutation, and the BglII-HindIII fragment was used to replace the corresponding wild type sequence in the Galpha s cDNA. Wild type and mutant Gsalpha cDNA were subcloned into the pCDNA3.1 expression vector (InVitrogen, Carlsbad, CA).

Analysis of Recombinant Wild Type and Mutant Galpha s-- LipofectAMINE (Life Technologies, Inc.) was used for transient transfection of HEK293 cells (2 × 106 in a T75 culture flask) with 8 µg of plasmid DNA. After incubation overnight, cells were replated into 24-well dishes (105 cells per well), and assays of cAMP production were performed 48 h later as described previously (26). The ratio of wild type Galpha s plasmid to receptor plasmid was determined empirically for each receptor to obtain optimized hormone-sensitive accumulation of cAMP. Triplicate measurements were made, and experiments were repeated at least three times. Data points were normalized for cell protein and expressed in terms of maximal cAMP accumulation in the presence of wild type Galpha s. Results are presented as the mean ± S.E. Data were analyzed with Prism software (version 2.0, GraphPad, San Diego, CA).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Clinical Presentation and Diagnosis-- The proband (subject III-3 in Fig. 1) and his two brothers were referred for evaluation of PHP when they were discovered to have elevated levels of serum PTH during an investigation of hypocalcemia. The three brothers had normal intellectual function and were at or above the 50th percentile for height; only one (III-3) of the three boys was obese (39 kg, >95th percentile) (Table I). Physical examination of the three boys, their unaffected sister, and their parents failed to disclose evidence of subcutaneous ossifications, brachydactyly, or other features of AHO, and radiographs of hands and feet were normal. All three brothers had elevated levels of intact PTH levels and failed to show a significant increase in the urinary excretion of nephrogenous cAMP after intravenous infusion of 200 units of synthetic human PTH-(1-34) (Table II). By contrast, their mother showed a normal urinary cAMP response to administration of human PTH-(1-34). Serum levels of magnesium, 25-(OH)-vitamin D, thyroxine, triiodothyronine, and TSH were within the normal range, and serum levels of testosterone were appropriate for age in all three boys (Table II). Subjects III-1 and III-2 showed pubertal LH and follicle-stimulating hormone responses to intravenous infusion of synthetic gonadotropin-releasing hormone (100 µg), and subject III-3 showed a prepubertal response. All studies were approved by the Joint Committee on Clinical Investigation of The Johns Hopkins University School of Medicine, and written informed consent was given by the study subjects or their parents.



View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Pedigree of family with pseudohypoparathyroidism type Ib. Panel shows the pedigree of the family and erythrocyte Galpha s levels. The arrow indicates the proband. Squares denote male family members and circles female family members. Half-filled symbols denote members with the Delta Ile382 mutation, and filled symbols denote those with both the gene mutation and PTH resistance. The level of immunoactive erythrocyte Galpha s is indicated below the symbol and represents the mean of three determinations.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Physical characteristics of the three affected brothers


                              
View this table:
[in this window]
[in a new window]
 
Table II
Laboratory evaluation

Semi-quantitative immunoblot analysis was performed in triplicate and demonstrated that levels of Galpha s protein (Fig. 1) were not reduced in erythrocyte membranes prepared from the three affected brothers (134 ± 8%) as compared with other unaffected family members (99.3 ± 2.1%) or a control group of unrelated normal subjects (92 ± 8%). To examine the functional activity of the erythrocyte Galpha s protein, we assessed the ability of detergent-solubilized Gs from erythrocyte membranes to reconstitute a hormonally responsive adenylyl cyclase system in membranes prepared from the cyc- clone of S49 murine lymphoma, which genetically lacks Galpha s protein (27). Addition of increasing amounts of erythrocyte membrane extract to constant amounts of cyc- membranes produced linear increases in L-isoproterenol (10 µM)-stimulated adenylyl cyclase activity, with regression slopes for the three affected members (III-1, III-2 III-3; 60.8 ± 4.3) and two members who were unaffected carriers (I-1 and II-2; 69.3 ± 2.0) that were equivalent (Fig. 2).



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Erythrocyte Galpha s activity. Galpha s activity in detergent extracts of erythrocyte membranes was determined by measuring the ability of various amounts of the extract to reconstitute hormone-response adenylyl cyclase activity in membranes prepared from the cyc- clone of S49 murine lymphoma cells, which genetically lack Galpha s (27). Addition of increasing amounts of erythrocyte membrane extract to constant amounts of cyc- membranes produced linear increases in L-isoproterenol (10 µM)-stimulated adenylyl cyclase activity, with regression slopes for the three affected members with PHP (III-1, III-2, and III-3; 60.8 ± 4.3) and two unaffected carriers with "PPHP" (I-2 and II-2; 69.3 ± 2.0) of the kindred that were equivalent. Results are representative of three separate experiments, each performed with triplicate determinations. Results are expressed as pmol of cyclic AMP per mg protein per 20 min of incubation.

Identification and Confirmation of GNAS1 Mutation-- No abnormalities were found in exons 1-12 of the proband's gene for Galpha s. Polyacrylamide gel electrophoresis (Fig. 3B) and DGGE (Fig. 3C) of DNA fragments amplified from exon 13 revealed additional bands indicating the presence of an abnormal allele. Although the typical pattern for heterozygous alleles on a denaturing gradient gel is composed of four bands, of which two bands represent homoduplex fragments and two bands represent heteroduplex fragments (28-30), DGGE of this PCR product consistently resolved only three bands. Thus, it is likely that under the conditions we employed the two slowly migrating heteroduplex fragments migrated as a single band on the denaturing gradient gel. The exon 13 PCR products were ligated into the plasmid vector pCRII, and DNA from individual clones was sequenced. Of 10 clones sequenced, 4 contained the wild type sequence for Galpha s exon 13. In addition, 6 clones contained inserts in which there was a 3-base pair deletion (CAT) that eliminated an isoleucine residue at position 382 (Delta Ile382) of Galpha s protein (Fig. 4). RT-PCR of Galpha s mRNA from peripheral blood mononuclear cells amplified equivalent amounts of wild type and mutant cDNA, indicating that mRNA derived from the mutant allele was stable (data not shown).



View larger version (66K):
[in this window]
[in a new window]
 
Fig. 3.   Analysis of exon 13 of GNAS1 gene. A shows the pedigree of a portion of the family; symbols are as described in Fig. 1. Exon 13 of GNAS1 was amplified by the polymerase chain reaction using genomic DNA as described under "Experimental Procedures." PCR products were analyzed by electrophoresis through nondenaturing polyacrylamide gels (B) or through polyacrylamide gels containing a linearly increasing concentration of the denaturants urea and formamide (C). Although the typical pattern for heterozygous alleles on a denaturing gradient gel is comprised of four bands, of which two bands represent homoduplex fragments and two bands represent heteroduplex fragments (28-30), DGGE of this PCR product consistently resolved only three bands. The two lower bands represent the mutant (lowest) and wild type (middle band) Galpha s sequences, whereas the upper-most band consists of the two slowly migrating heteroduplex fragments.



View larger version (43K):
[in this window]
[in a new window]
 
Fig. 4.   Sequence analysis of antisense strand of exon 13 of the GNAS1 gene. Exon 13 was amplified by PCR of genomic DNA from the propositus, and after ethanol precipitation the DNA was ligated into the plasmid vector pCRII. DNA from individual clones was sequenced as described under "Experimental Procedures." Sequence analysis showed a heterozygous mutation (wild type Normal Allele in left panel; mutant Abnormal Allele in right panel) in which one allele contained a 3-base pair deletion (CAT) that results in the in-frame loss of the isoleucine residue at codon 382.

To genotype the rest of the family, PCR products of exon 13 from all available members were analyzed by polyacrylamide gel electrophoresis and DGGE. DNA from the clinically unaffected mother (II-1, Fig. 3) and maternal grandfather showed patterns consistent with heterozygosity for the Delta Ile382 mutation, whereas DNA from all other family members migrated as single bands indicating homozygosity for the wild type GNAS1 allele (Fig. 3 and not shown). The Delta Ile382 mutation was not present in genomic DNA from 15 additional unrelated subjects with PHP type 1b or from 30 other normal, unrelated subjects (data not shown).

Functional Analysis of Recombinant Galpha s Protein-- The Delta Ile382 mutation occurs in the middle of the alpha 5 helix at the carboxyl terminus of the protein, a region that contributes importantly to receptor selectivity. The characteristics of the Delta Ile382 mutation were assessed by transiently expressing wild type and mutant forms of Galpha s plus cDNAs encoding G protein-coupled receptors in HEK293 cells at 37 °C. Immunoblot analyses revealed that the Galpha s containing the Delta Ile382 mutation was expressed at a level that was similar (118 ± 11%) to that of the wild type recombinant Galpha s protein under all experimental conditions (Fig. 5). Moreover, cells that expressed mutant or wild type Galpha s proteins produced similar agonist-dependent increases in cAMP when incubated with various concentrations of L-isoproterenol, which activates endogenous beta -adrenergic receptors (Fig. 6B). However, as the Bmax for isoproterenol stimulation was slightly reduced for the mutant Galpha s protein, we cannot exclude a subtle defect in coupling to beta -adrenergic receptors. To assess the functional effects of the Delta Ile382 mutation on receptor coupling, wild type and mutant forms of Galpha s were transiently coexpressed in HEK293 cells with specific receptors that can mediate activation of Gs but that are not found in HEK293 cells (31), and after incubation with various concentrations of hormones the production of cAMP was measured. Cells transfected with the human PTHR1 showed a concentration-dependent increase in intracellular cAMP accumulation after incubation with 10-11 to 10-7 M bPTH-(1-34), and this response was significantly enhanced in cells that had been cotransfected with the wild type Galpha s cDNA (Fig. 6A). By contrast, HEK293 cells that had been cotransfected with the cDNAs for the mutant Galpha s and hPTHR1 showed cAMP responses to PTH (Fig. 6A) and PTHrP (data not shown) that were no greater than those in cells that had been transfected with only the hPTHR1.



View larger version (53K):
[in this window]
[in a new window]
 
Fig. 5.   Immunoblot analysis of recombinant wild type and mutant Galpha s proteins. HEK293 cells were transfected with expression vectors (V) (pcDNA3.1) encoding the wild type (WT) or mutant (M) Galpha s proteins, plus expression vectors (pcDNA1/Amp) with no cDNA insert (Vector) or cDNA encoding the PTHR1 (PTH-Rc), the TSH receptor (TSH-Rc), or the LH receptor (LH-Rc). Cells were harvested by scraping with a Teflon policeman in a hypotonic lysis buffer (5 mM HEPES, pH 7.4, 0.5 mM EDTA) and were disrupted by 20 strokes of a Dounce homogenizer (loose-fitting) on wet ice. Membrane fractions were collected by centrifugation, and expression of Galpha s protein was determined by immunoblot analysis in which 50-µg samples of membrane protein were resolved by denaturing 10% SDS-PAGE, transferred to polyvinylidene difluoride membranes, and incubated with a rabbit polyclonal antibody (RM/1) directed against a carboxyl-terminal decapeptide of Galpha s. Antibody binding was detected using a 125I-labeled goat anti-rabbit antibody and a PhosphorImager. Markers indicate the overexpressed 52-kDa Galpha s as well as the endogenous 45-kDa Galpha s. At least two additional experiments for each cotransfection condition were performed and gave similar results.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Functional studies of the recombinant wild type and mutant Galpha s proteins. HEK293 cells were transfected with expression vectors (pcDNA3.1) encoding the wild type (WT) or mutant (MUT) Galpha s proteins, plus expression vectors (pcDNA1/Amp) encoding the PTHR1 (A), the TSH receptor (C), or the LH receptor (D). The cells were incubated for 10 min in the presence of increasing concentrations of the indicated agonist, and cyclic AMP was extracted and measured by radioimmunoassay. Each point represents the mean (±S.E.) of at least three experiments in which triplicate determinations were performed. The level of cyclic AMP is expressed in terms of maximal agonist-induced accumulation (100%) by cells expressing wild type Galpha s. Cells were transfected with 4 µg of plasmid containing PTHR1 or LH receptors plus 4 µg of Galpha s plasmid and 6 µg of plasmid containing TSH receptor plus 2 µg of Galpha s plasmid.

To assess the ability of the mutant Galpha s protein to couple to other heptahelical receptors, HEK293 cells were cotransfected with wild type or mutant Galpha s cDNAs plus cDNAs encoding the TSH receptor or LH receptor. After incubation with various concentrations of either bTSH or human chorionic gonadotropin, the accumulation of cAMP was measured. At all concentrations of hormone tested, cells expressing the wild type or mutant Galpha s cDNAs showed similar increases in cAMP that were significantly greater than those in cells expressing the receptor alone (Fig. 6, C and D).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PHP type Ib is characterized by isolated resistance to PTH and an absence of features of AHO, and thus appears to be biochemically and clinically distinct from PHP-type Ia. The identification of a novel germ line mutation, Delta Ile382, in the gene encoding Galpha s in three boys with PHP type Ib provides a new example of how an inactivating mutation of a widely expressed G protein can cause a limited disease. When expressed in vitro this mutant Galpha s was unable to couple to the PTHR1 but was able to interact normally with a variety of other heptahelical receptors (i.e. LH, TSH, and beta -adrenergic receptors) that require Galpha s to stimulate adenylyl cyclase. The ability of the mutant Galpha s protein to activate these other receptors normally effectively excludes defects in beta gamma subunit interaction and suggests another mechanism for the selective uncoupling from the PTHR1. Several lines of evidence indicate that these findings are the result of differential efficiency in receptor coupling rather than artifact owing from differences in Galpha s or receptor expression. First, semi-quantitative immunoblot analysis demonstrated equivalent expression of the mutant and wild type Galpha s recombinant proteins in each experimental paradigm, thus excluding differences in the relative amount of mutant Galpha s protein expressed with different receptors as the basis for the differential coupling to the various receptors. Second, although we did not quantify actual receptor levels, preliminary experiments were performed with each receptor cDNA and wild type Galpha s to determine the optimal amount of each plasmid to cotransfect to achieve maximal hormone responsiveness under each condition. Third, experiments were repeated at least three times for each combination of receptor and Galpha s protein to avoid random differences in receptor expression as a basis for differential responsiveness of the mutant Galpha s protein to different receptors.

The classical PTH receptor, PTHR1, is an ~75-kDa glycoprotein that is often referred to as the PTH/PTHrP receptor as it binds both PTH and parathyroid hormone-related protein (PTHrP), a factor made by diverse tumors that cause humorally mediated hypercalcemia, with equivalent affinity, and can activate both adenylyl cyclase and phospholipase C (32). As PTH and PTHrP share greatest homology in their amino termini, where the conserved sequences are critical for receptor binding and activation, it is likely that binding of these two peptides to the PTHR1 induces similar conformational changes in the receptor. It was therefore not surprising that the mutant Galpha s protein was also unable to couple to the PTHrP-stimulated PTHR1 receptor. Thus, isolated resistance to PTH, and the subsequent development of PHP type Ib in the three affected subjects in this family, can be explained by a GNAS1 mutation that produces an abnormal Galpha s molecule that, although widely expressed, is apparently unable to interact with only the PTHR1. By contrast, subjects with PHP type Ia have defective GNAS1 alleles that produce inadequate amounts of Galpha s or Galpha s molecules that are unable to interact with all receptors (33-35). The basis for AHO in subjects with PHP type Ia or their relatives with PPHP and normal hormone responsiveness remains unexplained, but the lack of AHO in these three affected boys provides further confirmation that defective signaling through the PTHR1 is unlikely to be the cause. Thus, abnormal growth of tubular bones, the presumptive basis for brachydactyly in AHO patients with GNAS1 mutations that completely inactivate Galpha s, may result from defective signaling through other adenylyl cyclase-coupled receptors that are expressed in the growth plate.

Selective receptor uncoupling in the patients described here was due to deletion of a single amino acid located in the carboxyl terminus of Galpha s, an essential region for receptor coupling and selectivity (reviewed in Ref. 36). The crystallographic structure of the 394-amino acid Galpha s molecule indicates that Ile382 lies within the alpha 5 helix, which together with the alpha 4-beta 6 loop form a plane on the back of Galpha s that may interact with receptors (37). Additional evidence that the alpha 5 helix and alpha 4-beta 6 loop contribute importantly to the receptor binding surface comes from patterns of evolutionary conservation (38) as well as from biochemical and genetic analyses. For example, peptide-specific antibodies directed against the last 10 amino acids of G-protein alpha  chains can block receptor-mediated regulation of adenylyl cyclase activity (39, 40), and experimentally produced mutations in this region uncouple Galpha s from receptors (41). In addition, naturally occurring mutations in the carboxyl terminus of Galpha s that inhibit coupling to all receptors have been identified in the unc mutant of the S49 murine lymphoma cell line (Arg389 right-arrow Pro, (42, 43)) and in a patient with PHP type Ia (Arg385 right-arrow His, (33)). Deletion of Ile382 could alter the kink in the midsection of the alpha 5 helix, thereby disrupting contact between the alpha 5 and alpha 4-beta 6 regions of the Galpha s chain. Specific uncoupling of the Delta Ile382 Galpha s chain from only the PTHR1 would imply that the interaction of Galpha s with the PTHR1 is particularly sensitive to this change in the three-dimensional structure of the alpha  chain. Support for the extraordinary specificity of this defect in receptor interaction derives from observations of differential efficacy of Galpha s-coupled receptors to activate chimeric forms of G proteins in which only the last five amino acid residues are derived from Galpha s (44). These studies suggest that other amino acids in the alpha 5 helix must contribute to the fidelity of receptor-G protein interaction.

That the same mutation could result in PHP type Ib in the three brothers but fail to produce any clinical effects in their mother and maternal grandfather is a remarkable discrepancy in genotype-phenotype relations (Figs. 1 and 2). The discrepancy in the maternal grandfather (I-1) might be explained by the presence of undetected mosaicism, but this explanation could not account for the lack of phenotypic features in his daughter (II-2), the mother of the three affected boys. The inconstant phenotypes exhibited in members of this family who share the same GNAS1 mutation are reminiscent of the peculiar pattern of inheritance of hormone resistance exhibited by patients with other GNAS1 gene mutations, in whom maternal transmission of Galpha s deficiency leads to PHP type Ia, whereas paternal transmission of the defect leads to PPHP (6), a variant characterized by somatic features of AHO but normal hormone responsiveness (45-48). These observations first suggested imprinting of the GNAS1 locus as a mechanism for gene regulation but could not anticipate the complex pattern of genomic imprinting now identified. Two upstream promoters, each associated with a large coding exon, lie 35-40 kilobase pairs upstream of GNAS1 exon 1 and generate unique proteins. In addition, a third alternative first exon, termed 1A, is only about 3 kilobase pairs upstream of exon 1, and lacks translated sequences (49). The more 5' of these exons encodes NESP55, which is expressed exclusively from the maternal allele. By contrast, the XLalpha s (50, 51) and 1A exons (52)2 are paternally expressed. Although initial studies in human tissues were consistent with biallelic expression of Galpha s (50, 51, 54), subsequent analyses in mice in which one Gnas allele is disrupted (Gnas +/-) have suggested a model of cell- or tissue-specific paternal imprinting of Galpha s. In this model, both Gnas alleles are expressed in most tissues, but only the maternal allele is expressed in some tissues (e.g. renal cortex) (55-57). Accordingly, Gnas +/- mice that inherit an inactivated Gnas allele maternally will lack any functional Galpha s protein in tissues in which Gnas is paternally imprinted, such as the PTH-sensitive renal proximal tubule, and will consequently develop PTH resistance. By contrast, Gnas +/- mice that inherit the inactive Gnas allele paternally will express only the wild type maternal allele in these tissues. As a consequence, these mice will have "normal" levels of Galpha s protein in renal cells and, like subjects with PPHP, will have normal PTH responsiveness. Finally, Gnas +/- mice and humans will have a 50% reduction in Galpha s expression in nonimprinted tissues, which express both Galpha s alleles. Biallelic expression would explain the similar 50% reduction in Galpha s activity in erythrocytes and cultured fibroblasts from subject with PHP type Ia or PPHP (19, 46), who inherit a defective GNAS1 allele from their mother or father, respectively. Moreover, hormone responsiveness in tissues that express both GNAS1 alleles would be normal (e.g. renal medulla and vasopressin) or mildly impaired (e.g. thyroid and TSH) based on whether 50% of the normal complement of Galpha s is sufficient for normal signal transduction. Biallelic expression of GNAS1 in bone cells could also explain the normal response of cultured bone cells from a patient with PHP type Ia to PTH treatment in vitro (58), as well as the development of hyperparathyroid bone disease by many patients with PHP type I who have elevated serum levels of PTH (53).

The prevalence of mutations in the GNAS1 gene as a cause of PHP type Ib remains to be determined, but our current studies indicate that defects in coding exons are unlikely to be common. However, recent molecular genetic analyses show linkage of PHP type Ib to the chromosomal region that composes the GNAS1 gene locus, as well as apparent paternal imprinting of PTH resistance (15), thus suggesting that mutations in or near the promoter region of GNAS1 are likely to be present in these patients. Such mutations may selectively reduce Galpha s expression in the renal proximal tubule and thereby impair PTH-dependent signaling in the kidney. Identification of these mutations will provide additional confirmation that defective regulation of Galpha s signaling is a common mechanism for PTH resistance in these two distinctive forms of PHP type I.


    ACKNOWLEDGEMENTS

We are grateful to Dr. Changlin Ding and Phillip M. Smallwood for expert technical assistance.


    FOOTNOTES

* This work was supported in part by United States Public Health Service Grant DK34281 (to M. A. L.) and by General Clinical Research Center Grant RR0035 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Division of Pediatric Endocrinology, Johns Hopkins University School of Medicine, Park Bldg., Rm. 211, 600 N. Wolfe St., Baltimore, Maryland 21287. Tel.: 410-955-6463; Fax: 410-955-9773; E-mail: mlevine@jhmi.edu.

Published, JBC Papers in Press, October 11, 2000, DOI 10.1074/jbc.M006032200

2 S. M. Jan de Beur, C. L. Ding, and M. A. Levine, unpublished data.


    ABBREVIATIONS

The abbreviations used are: PHP, pseudohypoparathyroidism; PPHP, pseudopseudohypoparathyroidism; PTH, parathyroid hormone; PTHrP, parathyroid hormone-related protein; PTHR1, type 1 PTH receptor; G protein, guanine nucleotide-binding protein; Gs, stimulatory G protein; Galpha s, alpha chain of Gs; Delta Ile382, Galpha s mutant with deletion of Ile382 AHO, Albright hereditary osteodystrophy; PPHP, pseudopseudohypoparathyroidism; bTSH, bovine thyrotropic hormone; PCR, polymerase chain reaction; DGGE, denaturing gradient gel electrophoresis; RT-PCR, reverse transcription-PCR; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; LH, luteinizing hormone; TSH, thyrotropic hormone.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Albright, F., Burnett, C. H., and Smith, P. H. (1942) Endocrinology 30, 922-932
2. Levine, M. A. (2000) in Endocrinology (DeGroot, L. J., ed), 4th Ed. , pp. 1133-1153, W. B. Saunders Co., Philadelphia
3. Levine, M. A., Downs, R. W., Jr., Moses, A. M., Breslau, N. A., Marx, S. J., Lasker, R. D., Rizzoli, R. E., Aurbach, G. D., and Spiegel, A. M. (1983) Am. J. Med. 74, 545-556[Medline] [Order article via Infotrieve]
4. Levine, M. A. (1999) J. Bone Miner. Res. 14, 1255-1260[Medline] [Order article via Infotrieve]
5. Patten, J. L., Johns, D. R., Valle, D., Eil, C., Gruppuso, P. A., Steele, G., Smallwood, P. M., and Levine, M. A. (1990) N. Engl. J. Med. 322, 1412-1419[Abstract]
6. Albright, F., Forbes, A. P., and Henneman, P. H. (1952) Trans. Assoc. Am. Physicians 65, 337-350
7. Winter, J. S. D., and Hughes, I. A. (1980) Can. Med. Assoc. J. 123, 26-31[Abstract]
8. Nusynowitz, M. L., Frame, B., and Kolb, F. O. (1976) Medicine (Baltimore) 55, 105-125[Medline] [Order article via Infotrieve]
9. Schipani, E., Weinstein, L. S., Bergwitz, C., Iida-Klein, A., Kong, X. F., Stuhrmann, M., Kruse, K., Whyte, M. P., Murray, T., Schmidtke, J., Van Dop, C., Brickman, A. S., Crawford, J. D., Potts, J. T., Jr., Kronenberg, H. M., Abou-Samra, A. B., Segre, G. V., and Juppner, H. (1995) J. Clin. Endocrinol. & Metab. 80, 1611-1621[Abstract]
10. Bettoun, J. D., Minagawa, M., Kwan, M. Y., Lee, H. S., Yasuda, T., Hendy, G. N., Goltzman, D., and White, J. H. (1997) J. Clin. Endocrinol. & Metab. 82, 1031-1040[Abstract/Free Full Text]
11. Fukumoto, S., Suzawa, M., Takeuchi, Y., Kodama, Y., Nakayama, K., Ogata, E., Matsumoto, T., and Fujita, T. (1996) J. Clin. Endocrinol. & Metab. 81, 2554-2558[Abstract]
12. Lanske, B., Karaplis, A. C., Lee, K., Luz, A., Vortkamp, A., Pirro, A., Karperien, M., Defize, L. K., Ho, C., Mulligan, R. C., Abou-Samra, A. B., Juppner, H., Segre, G. V., and Kronenberg, H. M. (1996) Science 273, 663-666[Abstract]
13. Jobert, A. S., Zhang, P., Couvineau, A., Bonaventure, J., Roume, J., Le Merrer, M., and Silve, C. (1998) J. Clin. Invest. 102, 34-40[Abstract/Free Full Text]
14. Allen, D. B., Friedman, A. L., Greer, F. R., and Chesney, R. W. (1988) Am. J. Med. Genet. 31, 153-158[Medline] [Order article via Infotrieve]
15. Juppner, H., Schipani, E., Bastepe, M., Cole, D. E., Lawson, M. L., Mannstadt, M., Hendy, G. N., Plotkin, H., Koshiyama, H., Koh, T., Crawford, J. D., Olsen, B. R., and Vikkula, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11798-11803[Abstract/Free Full Text]
16. Adams, A. E., Pines, M., Nakamoto, C., Behar, V., Yang, Q. M., Chorev, M., Rosenblatt, M., Levine, M. A., and Suva, L. J. (1995) Biochemistry 34, 10553-10559[Medline] [Order article via Infotrieve]
17. Cain, C. D., Adey, W. R., and Luben, R. A. (1987) J. Bone. Miner. Res. 2, 437-441[Medline] [Order article via Infotrieve]
18. Gierschik, P., Codina, J., Simons, C., Birnbaumer, L., and Spiegel, A. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 727-731[Abstract]
19. Patten, J. L., and Levine, M. A. (1990) J. Clin. Endocrinol. & Metab. 71, 1208-1214[Abstract]
20. Miric, A., Vechio, J. D., and Levine, M. A. (1993) J. Clin. Endocrinol. & Metab. 76, 1560-1568[Abstract]
21. Jan de Beur, S. M., Deng, Z., Ding, C. L., and Levine, M. A. (1998) Proceedings of the 80th Annual Meeting of the Endocrine Society, New Orleans , p. 62, Endocrine Society, Bethesda, MD (abstr. OR7-6)
22. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467[Abstract]
23. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299[Medline] [Order article via Infotrieve]
24. Namnoum, A. B., Merriam, G. R., Moses, A. M., and Levine, M. A. (1998) J. Clin. Endocrinol. & Metab. 83, 824-829[Abstract/Free Full Text]
25. Gejman, P. V., Weinstein, L. S., Martinez, M., Spiegel, A. M., Cao, Q., Hsieh, W. T., Hoehe, M. R., and Gershon, E. S. (1991) Genomics 9, 782-783[Medline] [Order article via Infotrieve]
26. Levine, M. A., Eil, C., Downs, R. W., Jr., and Spiegel, A. M. (1983) J. Clin. Invest. 72, 316-324[Medline] [Order article via Infotrieve]
27. Sullivan, K. A., Liao, Y. C., Alborzi, A., Beiderman, B., Chang, F. H., Masters, S. B., Levinson, A. D., and Bourne, H. R. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 6687-6691[Abstract]
28. Fischer, S. G., and Lerman, L. S. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 1579-1583[Abstract]
29. Myers, R. M., Fischer, S. G., Maniatis, T., and Lerman, L. S. (1985) Nucleic Acids Res. 13, 3111-3129[Abstract]
30. Myers, R. M., Maniatis, T., and Lerman, L. S. (1987) Methods Enzymol. 155, 501-527[Medline] [Order article via Infotrieve]
31. Chabre, O., Conklin, B. R., Brandon, S., Bourne, H. R., and Limbird, L. E. (1994) J. Biol. Chem. 269, 5730-5734[Abstract/Free Full Text]
32. Schipani, E., Karga, H., Karaplis, A. C., Potts, J. T., Jr., Kronenberg, H. M., Segre, G. V., Abou-Samra, A. B., and Juppner, H. (1993) Endocrinology 132, 2157-2165[Abstract]
33. Schwindinger, W. F., Miric, A., Zimmerman, D., and Levine, M. A. (1994) J. Biol. Chem. 269, 25387-25391[Abstract/Free Full Text]
34. Warner, D. R., Gejman, P. V., Collins, R. M., and Weinstein, L. S. (1997) Mol. Endocrinol. 11, 1718-1727[Abstract/Free Full Text]
35. Warner, D. R., Weng, G., Yu, S., Matalon, R., and Weinstein, L. S. (1998) J. Biol. Chem. 273, 23976-23983[Abstract/Free Full Text]
36. Bourne, H. R. (1997) Curr. Opin. Cell Biol. 9, 134-142[CrossRef][Medline] [Order article via Infotrieve]
37. Sunahara, R. K., Tesmer, J. J., Gilman, A. G., and Sprang, S. R. (1997) Science 278, 1943-1947[Abstract/Free Full Text]
38. Lichtarge, O., Bourne, H. R., and Cohen, F. E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7507-7511[Abstract/Free Full Text]
39. Spiegel, A. M., Simonds, W. F., Jones, T. L., Goldsmith, P. K., and Unson, C. G. (1990) Biochem. Soc. Symp. 56, 61-69[Medline] [Order article via Infotrieve]
40. Simonds, W. F., Goldsmith, P. K., Woodard, C. J., Unson, C. G., and Spiegel, A. M. (1989) FEBS Lett. 249, 189-194[CrossRef][Medline] [Order article via Infotrieve]
41. Pantaloni, C., and Audigier, Y. (1993) J. Recept. Res. 13, 591-608[Medline] [Order article via Infotrieve]
42. Sullivan, K. A., Miller, R. T., Masters, S. B., Beiderman, B., Heideman, W., and Bourne, H. R. (1987) Nature 330, 758-760[CrossRef][Medline] [Order article via Infotrieve]
43. Rall, T., and Harris, B. A. (1987) FEBS Lett. 224, 365-371[CrossRef][Medline] [Order article via Infotrieve]
44. Conklin, B. R., Herzmark, P., Ishida, S., Voyno-Yasenetskaya, T. A., Sun, Y., Farfel, Z., and Bourne, H. R. (1996) Mol. Pharmacol. 50, 885-890[Abstract]
45. Wilson, L. C., Oude Luttikhuis, M. E., Clayton, P. T., Fraser, W. D., and Trembath, R. C. (1994) J. Med. Genet. 31, 835-839[Abstract]
46. Levine, M. A., Jap, T. S., Mauseth, R. S., Downs, R. W., and Spiegel, A. M. (1986) J. Clin. Endocrinol. & Metab. 62, 497-502[Abstract]
47. Davies, S. J., and Hughes, H. E. (1993) J. Med. Genet. 30, 101-103[Abstract]
48. Nakamoto, J. M., Sandstrom, A. T., Brickman, A. S., Christenson, R. A., and Van Dop, C. (1998) Am. J. Med. Genet. 77, 261-267[CrossRef][Medline] [Order article via Infotrieve]
49. Swaroop, A., Agarwal, N., Gruen, J. R., Bick, D., and Weissman, S. M. (1991) Nucleic Acids Res. 17, 4725-4729
50. Hayward, B. E., Moran, V., Strain, L., and Bonthron, D. T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15475-15480[Abstract/Free Full Text]
51. Hayward, B. E., Kamiya, M., Strain, L., Moran, V., Campbell, R., Hayashizaki, Y., and Bonthron, D. T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 10038-10043[Abstract/Free Full Text]
52. Liu, J., Yu, S., Litman, D., Chen, W., and Weinstein, L. S. (2000) Mol. Cell. Biol. 20, 5808-5817[Abstract/Free Full Text]
53. Burnstein, M. I., Kottamasu, S. R., Pettifor, J. M., Sochett, E., Ellis, B. I., and Frame, B. (1985) Radiology 155, 351-356[Abstract]
54. Campbell, R., Gosden, C. M., and Bonthron, D. T. (1994) J. Med. Genet. 31, 607-614[Abstract]
55. Yu, S., Yu, D., Lee, E., Eckhaus, M., Lee, R., Corria, Z., Accili, D., Westphal, H., and Weinstein, L. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8715-8720[Abstract/Free Full Text]
56. Weinstein, L. S., Yu, S., and Ecelbarger, C. A. (2000) Am. J. Physiol. 278, F507-F514[Abstract/Free Full Text]
57. Schwindinger, W. F., Lawler, A. M., Gearhart, J. D., and Levine, M. A. (1998) Proceedings of the 80th Annual Meeting of the Endocrine Society, New Orleans , p. 480, Endocrine Society, New Orleans
58. Murray, T. M., Rao, L. G., Wong, M. M., Waddell, J. P., McBroom, R., Tam, C. S., Rosen, F., and Levine, M. A. (1993) J. Bone Miner. Res. 8, 83-91[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.